It’s hard to overstate how well $Hims & Hers Health Inc.(HIMS)$ is performing. The company reported 111% growth in the first quarter and is now profitable and generating consistent free cash flow.
Management also expects margins to continue expanding 1-3% per year, so in time, this could be a 10-20% operating margin business.
Growth in the quarter was certainly driven by GLP-1s, which were still in shortage in the first quarter, allowing Hims & Hers to compound the product and sell it to subscribers at a low price.
That shortage ended early in Q2, so growth will slow in the final three quarters of the year, but management is still expecting 56% to 63% revenue growth in 2025, despite the loss of the compounded GLP-1 exemption.
A recent partnership with $Novo-Nordisk A/S(NVO)$ to sell Wegovy for $599 per month will include Hims & Hers’ “holistic solutions” like activity and meal plans, which tie into the AI announcements that came this week that I’ll get to below.
What we’re seeing is Hims & Hers become the aggregator of demand that we want it to be.
Put another way, people choose to go to Hims & Hers over going to their doctor. That’s the best sign of success in a digital business.
Once Hims & Hers has aggregated demand, it can pull together more supply and put pressure on those suppliers to provide better prices and more access.
The pressure that Hims & Hers is putting by aggregating millions of patients who need choice, I think, is a huge component, and why some of the most important medicines of the last decade and probably the next decade are now being priced in the hundreds of dollars, not thousands of dollars range. So we want to be a party to everybody in the ecosystem, but we also want to put the consumer first ahead of all.
Andrew Dudum, CEO
Going All-In
On top of the great results released on Monday, last night we learned Hims & Hers is offering up to $1 billion of convertible notes due 2030 with a 0% coupon. Here are the details.
$870 million convertible note sale
Could increase another $130 million for “overallotment”
Matures on May 15, 2030
Hims & Hers will have $0 interest payments until maturity
At maturity, the debt will be paid back with cash or stock at a conversion rate of $70.67 per share
Hims & Hers did enter into a capped call transaction to reduce the impact of dilution: The cap price of the capped call transactions will initially be $89.95 per share, which represents a premium of 75.0% over the last reported sale price of the Company’s Class A common stock of $51.40 per share on May 8, 2025, and is subject to certain adjustments under the terms of the capped call transactions.
What is Hims & Hers going to do with $1 billion?
I think the real answer is that Hims & Hers is going into aggressive expansion mode. It could acquire more testing and production facilities. I wouldn’t be surprised to see more international expansion. There may even be an opportunity to acquire a struggling competitor or two.
If AI is a big part of the future, I also wonder if Hims & Hers needs to build out its own data centers or solutions to be HIPAA compliant (I’m speculating here, I’m not an expert on HIPAA).
No matter what Hims & Hers does, this is a company hitting on all cylinders, and I like the aggressive move to solidify its position as an aggregator.
The stock has been a rocket ship, but it’s still not expensive at 6.3x sales.
Congratulations to all Asymmetric Investors who are up big on Hims & Hers. Here’s to celebrating this week’s win and to more in the future!
For whom haven't open CBA can know more from below:
🏦 Open a CBA today and enjoy privileges of up to SGD 20,000 in trading limit with 0 commission. Trade SG, HK, US stocks as well as ETFs unlimitedly!
Find out more here：
Trade on a Cash Boost Account and enjoy up to 6 months of Commission-Free trading.
💰Join the TB Contra Telegram Group to Get $10 Trading Vouchers Now🎉
Comments